Product
AVR-RD-02
2 clinical trials
1 indication
Indication
Gaucher's DiseaseClinical trial
The Guard1 Trial, an Open-Label, Multinational Phase 1/2 Study of the Safety and Efficacy of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-02 for Subjects With Type 1 Gaucher DiseaseStatus: Terminated, Estimated PCD: 2023-08-21
Clinical trial
A Long-Term Follow-Up Safety Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02Status: Active (not recruiting), Estimated PCD: 2037-06-01